Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 4/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9496731 | 0.86 | CHRNA7 (0.50) | HTR1ACHRNA7IDO1HSD11B1 | |
| SCHEMBL9493953 | 0.80 | CHRNA7 (0.50) | CHRNA7IDO1 | |
| SCHEMBL27014175 | 0.79 | SIGMAR1 (0.39) | HTR1AIDO1HSD11B1SRD5A1 | |
| SCHEMBL4119985 | 0.73 | CNR2 (0.43) | ACHEPOLBCHRNA7IDO1 | |
| SCHEMBL4119991 | 0.73 | CNR2 (0.43) | ACHEPOLBCHRNA7IDO1 | |
| SCHEMBL4119987 | 0.73 | CNR2 (0.43) | ACHEPOLBCHRNA7IDO1 | |
| SCHEMBL27014161 | 0.72 | CYP11B2 (0.42) | IDO1 | |
| SCHEMBL7623817 | 0.71 | SLC18A3 (0.45) | CHRNA7 | |
| SCHEMBL7620129 | 0.71 | SLC18A3 (0.45) | CHRNA7 | |
| SCHEMBL7620113 | 0.71 | SLC18A3 (0.45) | CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018146-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018146-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ, INC. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018146-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | PINK1, NME4, AK2 | ACHE 1644/4885POLB 759/4885HTR1A 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.